Reading LNAI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LNAI free→Reading LNAI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LNAI free→QuarterlyIQ Insights · LNAI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of the Original Report is hereby amended to include the following disclosures: On April 28, 2026, Lunai Bioworks, Inc. (the “ Company ”) received a staff determination letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) formally notifying the Company that, based upon its continued non-compliance with the $35,000,000 market value of listed securities (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “ MVLS Rule ”) upon the expiration o…
above, the Company does not believe that the acquisition of Holdings constitutes the acquisition of a “business” within the meaning of Rule 11-01(d) of Regulation S-X. Accordingly, the Company does not believe that financial statements of Holdings are required to be filed pursuant to Rule 3-05 of Regulation S-X. (b) Pro Forma Financial Information. Not applicable, for the reasons set forth in paragraph (a) above. See also Article 11 of Regulation S-X. (d) Exhibits. Exhibit No. Description 2.1…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on February 6, 2026, the Company received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market. The Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”), which stayed the delisting actio…
Unregistered Sales of Equity Securities. The disclosure set forth under
by reference. On May 1, 2026, in connection with the closing of the Merger and the issuance of the Series B Preferred Stock, the Company filed the Certificate of Designation of Series B Convertible Preferred Stock with the Secretary of State of the State of Delaware, designating the Series B Preferred Stock and fixing the rights, preferences, privileges and restrictions thereof. The issuance of the Series B Preferred Stock and the filing of the Certificate of Designation may be deemed to mate…
above is incorporated herein by reference. On May 1, 2026, the Company issued an aggregate of eight (8) shares of Series B Preferred Stock to the Holders as Merger Consideration, of which five (5) shares were issued to Oncotelic Inc. and three (3) shares were issued to Pelerin Therapeutics Inc. The Series B Preferred Stock has a per-share Stated Value of $2,500,000 and an aggregate Stated Value of $20,000,000. The maximum number of shares of common stock issuable upon full conversion of the S…
Entry into a Material Definitive Agreement On March 24, 2026, Lunai Bioworks, Inc. (the “Company”) entered into separate debt exchange agreements (collectively, the “Debt Exchange Agreements”) with three of the Company’s holders (each a “Holder”) of secured promissory notes (the “Investor Notes”). Pursuant to the Debt Exchange Agreements, the Holders agreed to cancel and extinguish an aggregate of $828,770.14 of outstanding principal and accrued interest owed under the Investor Notes in excha…
Unregistered Sales of Equity Securities The information set forth under the heading “Debt Exchange Agreements” in
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 6, 2026, Lunai Bioworks Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined to delist the Company’s securities from Nasdaq. As previously disclosed, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the St…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 6, 2026, Lunai Bioworks, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2…
Regulation FD Disclosure. In accordance with Nasdaq Listing Rule 5810(b), the Company is issuing this Current Report on Form 8-K to publicly disclose receipt of the Nasdaq staff determination letter described above. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intentions, plans, and expectations with respect to any appeal of…
Entry into a Material Definitive Agreement. On December 2, 2025, Lunai Bioworks, Inc. (the “Company”) entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with Dawson James Securities, Inc. (the “Sales Agent”), pursuant to which the Company may offer and sell (the “Offering”) shares of its common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $11.70 million, from time to time through the Sales Agent as the Company’s sales agen…
Unregistered Sales of Equity Securities On November 24, 2025, Lunai Bioworks Inc. (“Lunai” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company agreed to sell, and the Investor agreed to purchase, in a private placement, 3,133,333 shares of its common stock, par value $0.001 per share (the “Shares”), at a purchase price of $1.00 per share, and 1,044,444 three-year warrants, executa…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 27, 2025, Lunai Bioworks (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $35 million minimum Market Value of Listed Securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2) for Capital Market. The Notice state…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 15, 2025, Lunai Bioworks (the “Company”) received a Notice from the NASDAQ Stock Market that the Company has regained compliance with Listing Rule 5550(a)(2). On April 14, 2025, the NASDAQ staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous thirty (30) consecutive business days as required by the Listing Rules of the NAS…
Material Modification to Rights of Security Holders. To the extent required by
Material Impairments In connection with the bankruptcy described in Item 8.01, management determined on September 2, 2025 that a material impairment of assets has occurred. The Company expects to record an impairment charge for the quarter ending September 30, 2025, however, is unable to make a good faith estimate of the same or the cash expenditures resulting from the impairment charge, if any, at the time of this filing. The Company expects to report the impairment charge in its quarterly r…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 7, 2025, Renovaro Inc. (the “Company”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. On August 5, 2025, the Company received written confirmation from Nasdaq th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 22, 2025, Maurice van Tilburg, Chairman of the Board of Directors notified the Board of Directors of Renovaro Inc. of his resignation as Chairman of the Board, effective August 22, 2025. Mr. Tilburg’s resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. The resi…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On July 7, 2025, Renovaro Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5620(a), which requires that listed companies hold an annual meeting of shareholders no later than one year after the end of their fiscal year…
Entry into a Material Definitive Agreement. On July 7, 2025, Renovaro Inc. (“Renovaro”) entered into an Exchange Agreement (the “Exchange Agreement”) with certain accredited investors (the “Investors”), all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate of $9.7 million in outstanding secured promissory notes (the “Secured Notes”) for $16.1 million in new convertible promissory notes (the “Convertible Notes”),…
Unregistered Sales of Equity Securities. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 30, 2025, Maurice van Tilburg notified Renovaro Inc. (the “Company”) of his intent to resign from the office of Chief Executive Officer of GEDi Cube B.V., a wholly-owned indirect subsidiary of the Company, which resignation was effective May 30, 2025. Mr. van Tilburg’s resignation is not as a result of any disagreement with the Company or it…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On April 14, 2025, Renovaro Inc. (the “ Company ”) received a deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) informing the Company that its common stock, par value $0.0001 per share (the “ Common Stock ”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of…
Unregistered Sales of Equity Securities. The disclosure set forth in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.